July 7, 2016 07:08 AM EDTUpdated July 10, 02:16 PM

AbbVie preps franchise decision after Ablynx’s IL-6 drug goes head-to-head against Actemra

AbbVie was willing to bet up to $840 million that Ablynx’s nanobody tech could help it protect and expand its $14 billion megafranchise for Humira …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ab­b­Vie preps fran­chise de­ci­sion af­ter Abl­ynx’s IL-6 drug goes head-to-head against Actem­ra